Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low – Time to Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $19.60 and last traded at $19.71, with a volume of 41866 shares trading hands. The stock had previously closed at $20.16.

Wall Street Analysts Forecast Growth

Several analysts have commented on GPCR shares. William Blair started coverage on Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating on the stock. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities restated a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Price Performance

The company has a market capitalization of $1.23 billion, a PE ratio of -28.95 and a beta of -2.35. The company has a 50-day moving average of $25.60 and a two-hundred day moving average of $32.66.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, research analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its position in Structure Therapeutics by 2.9% during the third quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after purchasing an additional 221,851 shares in the last quarter. FMR LLC raised its holdings in Structure Therapeutics by 6.7% during the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after acquiring an additional 383,635 shares during the period. Janus Henderson Group PLC raised its holdings in Structure Therapeutics by 5.1% during the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company’s stock valued at $112,816,000 after acquiring an additional 203,010 shares during the period. Deep Track Capital LP raised its holdings in Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock valued at $75,936,000 after acquiring an additional 1,579,492 shares during the period. Finally, Vestal Point Capital LP raised its holdings in Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after acquiring an additional 575,000 shares during the period. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.